This workshop aims to support healthcare professionals with the clinical application of adaptive servo-ventilation (ASV)* – first by discussing the evidence base for the effects of ASV and the patients who may benefit from it, then exploring how this evidence can be used to help manage patients on ASV treatment and rounding things off with a Q&A with the experts.
1. What evidence-based medicine says about ASV therapy
Introducing the topic, Prof Michael Arzt examines:
- Who is being treated with ASV: Results from the READ-ASV and SCHLAF-XT-investigators.
- What the effects of ASV are on patients, based on evidence from both RCTs and registries.
2. The practicalities of ASV therapy
Prof Jean-Louis Pépin explains what the evidence means for the clinical use of ASV, with a focus on:
- The most frequent indications for ASV, based on real-life data.
- The basic mechanisms of central sleep apnoea (CSA), with a view to understanding both ASV and its settings.
- Two clinical patient cases that illustrate the use, settings and effectiveness of ASV in practice.
3. Q&A session
The workshop wraps up with more informative insights, as Chairs Anita Simonds and Holger Woehrle open the floor to the audience. Their questions on how to evaluate treatment success and when to switch a patient from CPAP to ASV provoke interesting discussions among the panel of experts.
This presentation is intended for health professionals only
This workshop is sponsored by ResMed
*ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF ≤ 45%) and moderate to severe predominant central sleep apnoea.
